Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Extensions’ Cost To Be Evaluated By FDA Under Ag Approps Request

Executive Summary

FDA will report on the costs to consumers of drug patent extensions by March

You may also be interested in...



FDA Generic Drug Promotional Campaign Features Newspaper Articles

FDA's educational campaign to encourage the use of generic drugs will be launched in late July with an informational article appearing in local newspapers nationwide

FDA Generic Drug Promotional Campaign Features Newspaper Articles

FDA's educational campaign to encourage the use of generic drugs will be launched in late July with an informational article appearing in local newspapers nationwide

FDA Patent Listing Procedures May Need Revision, Hatch And Waxman Say

FDA should apply more judgment in analyzing patents submitted for listing in the "Orange Book" when generic competition is imminent, Sens. Kennedy (D-Mass.) and Hatch (R-Utah) and Rep. Waxman (D-Calif.) said in a letter to HHS Secretary Thompson.

UsernamePublicRestriction

Register

PS038872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel